Sobell, J. M.; Elewski, B.; Banerjee, S.; Balagula, E.; Scharnitz, T.; Berger, V.; Hoyt, K.; Yamauchi, P.; Bettencourt, M.; Cameron, M. C.; Lebwohl, M. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI). J of Skin 2023, 7, s238.